Pregnant patients were excluded from the clinical trials that evaluated the safety and efficacy for the treatment of COVID-19, but preliminary reports of use in pregnant patients through the<unk>  compassionate use program are reassuring.
Among 86 pregnant and postpartum hospitalized patients with severe COVID-19 who received compassionate use<unk> , the therapy was well tolerated, with a low rate of serious adverse events.
Should not be withheld from pregnant patients if it is otherwise indicated.
No data
Adult: Unknown
Pediatric: Unknown
Adult: Unknown
Pediatric: Unknown
Remdesivir
Ritonavir
Molnupiravir
Lopinavir
Foscarnet
Raltegravir
Baloxavir marboxil
Ribavirin